FocalTherics (NASDAQ:FOCL) Stock Has Average Price Target of $7.75

Shares of FocalTherics (NASDAQ:FOCL) have been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $7.75.

FOCL has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a report on Tuesday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Mizuho set a $15.00 price target on shares of FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Piper Sandler reiterated a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th.

Insider Transactions at FocalTherics

In other news, Director David R. Horn acquired 10,000 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $47,500. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Lance Willsey bought 50,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the purchase, the director owned 1,291,780 shares in the company, valued at $6,135,955. The trade was a 4.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 116,000 shares of company stock valued at $551,000. Insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On FocalTherics

A number of hedge funds have recently modified their holdings of the business. Rock Springs Capital Management LP lifted its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 91,500 shares in the last quarter. Flax Pond Capital LLC acquired a new position in shares of FocalTherics during the 4th quarter worth approximately $2,623,000. Lido Advisors LLC purchased a new stake in shares of FocalTherics in the first quarter valued at approximately $40,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of FocalTherics in the first quarter valued at approximately $38,000. 62.74% of the stock is currently owned by institutional investors and hedge funds.

FocalTherics Price Performance

FocalTherics stock opened at $4.19 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 1.38. The stock has a market capitalization of $157.25 million, a PE ratio of -4.07 and a beta of -0.06. The firm has a 50 day simple moving average of $4.56. FocalTherics has a 12 month low of $1.75 and a 12 month high of $6.40.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The company had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. On average, equities research analysts anticipate that FocalTherics will post -0.82 EPS for the current fiscal year.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.